Widely used in the pharmaceutical industry as a key component in proton pump inhibitors (PPIs), this (R)-enantiomer is effective in reducing gastric acid production. It is primarily employed in the treatment of gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. Due to its enantiomeric purity, it provides a defined pharmacokinetic profile distinct from racemic mixtures. It is often formulated in enteric-coated tablets to protect the compound from degradation in the acidic environment of the stomach, ensuring targeted release in the small intestine for optimal absorption.